Q-omics provides the consensus-scored MIR559 profile across patient tissues and cancer cell-line models. MIR559 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MIR559 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, MIR559 RNA expression shows 15,046 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight MESO, KIRC, and ESCA as cancer lineages where MIR559 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR559 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR559 survival associations across molecular data types. MIR559 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR559 RNA expression–survival associations across cancer types. High MIR559 expression shows unfavorable associations in MESO, SKCM, THYM, THCA and READ, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for MIR559 RNA expression.
This table summarizes MIR559 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR559. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR559 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in BLCA, LUAD and STAD. The KIRC box plot shows higher MIR559 RNA expression in normal versus tumor tissue (log2 FC = −0.713, t-test p < 0.001).
This table shows molecular features associated with MIR559 in patient tissues and cancer cell lines. In patient samples, MIR559 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
